The purpose of the Career Development Program (CDP) is to identify and train outstanding investigators who are committed to pursuing a career in translational skin cancer research. The program will primarily assist junior faculty in their career development, but more established investigators interested in refocusing their research efforts in melanoma/skin cancer may also be considered. Women and underrepresented minorities will be strongly encouraged to participate. The team of distinguished clinicians, educators and researchers will ensure implementation of the specific aims of this program which are as follows:
Specific aim 1 : To identify and select translational research investigators who will develop independent research careers in melanoma and/or skin cancer.
Specific aim 2 : To provide Career Development Awardees with formal training and mentorship from both the clinical and laboratory perspectives in order to establish successful independent careers in translational research. We require that award recipients be active in SPORE functions, use the SPORE Core resource, and provide formal written progress reports. Within the context of the CDP, we have established high standards and expectations of the research mentors and a structured, formalized program of mentorship for the CDP awardees. The program measures success by resulting publications, resulting funding, and career advancement and ultimately independent careers in translational research. We have an outstanding talent pool and an effective training and mentorship program which will result in an exceptional group of skin cancer researchers.
|Vitiello, Marianna; Tuccoli, Andrea; D'Aurizio, Romina et al. (2017) Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget 8:25395-25417|
|Krepler, Clemens; Sproesser, Katrin; Brafford, Patricia et al. (2017) A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Rep 21:1953-1967|
|Yang, Lu; Zhang, Youyou; Shan, Weiwei et al. (2017) Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med 9:|
|Huang, Alexander C; Postow, Michael A; Orlowski, Robert J et al. (2017) T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545:60-65|
|Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2017) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15|
|Somasundaram, Rajasekharan; Zhang, Gao; Fukunaga-Kalabis, Mizuho et al. (2017) Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat Commun 8:607|
|Rebecca, Vito W; Nicastri, Michael C; McLaughlin, Noel et al. (2017) A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. Cancer Discov 7:1266-1283|
|Piao, Shengfu; Ojha, Rani; Rebecca, Vito W et al. (2017) ALDH1A1 and HLTF modulate the activity of lysosomal autophagy inhibitors in cancer cells. Autophagy 13:2056-2071|
|Zhang, Dongmei; Zhang, Gao; Hu, Xiaowen et al. (2017) Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer. Cancer Res 77:3745-3757|
|Behera, Reeti; Kaur, Amanpreet; Webster, Marie R et al. (2017) Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho. Clin Cancer Res 23:3181-3190|
Showing the most recent 10 out of 59 publications